+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases



Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases



Dermatology 228(2): 136-144



Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking. The aims of the present study were to evaluate the efficacy of propranolol for the treatment of IH, to identify favorable prognostic factors in propranolol-treated IH, and to evaluate the safety of propranolol for the treatment of IH. Clinical data were recorded from the electronic files and digital photographs of 99 patients with IH attending a tertiary pediatric medical center (2008-2011). Findings were evaluated by regression in volume and color changes. The male-to-female ratio was 1:4. Age at treatment initiation was 9.4 ± 10.1 months; 15% of the treated hemangiomas were beyond the proliferative phase (17-54 months). The propranolol starting dose was 2 mg/kg/day. Duration of the treatment was 8.5 ± 3.2 months. All but 1 patient responded to treatment. A longer treatment course was required for segmental and deep hemangiomas. Mild side effects occurred in 32% of patients. Recurrence occurred in 13% of patients. Lesions located on the face are better responders when treatment is started early. Treatment should continue up to age 12-15 months, with a longer course for segmental or deep hemangiomas.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052896932

Download citation: RISBibTeXText

PMID: 24556822

DOI: 10.1159/000351557


Related references

A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma. Korean Journal of Pediatrics 58(12): 484-490, 2015

Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. Journal of Pediatric Hematology/Oncology 35(7): 493-499, 2013

Efficacy and safety of oral propranolol for infantile hemangioma in Japan. Pediatrics International 59(8): 869-877, 2017

Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatology 153(6): 529-536, 2017

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics 138(4):, 2016

Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. Medicine 98(4): E14078, 2019

Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma. Hormone Research in Paediatrics 78(4): 256-260, 2012

Infantile hemangioma: Efficacy of low-dose propranolol and of intralesional bleomycin injection for propranolol non-response. Pediatrics International 61(5): 459-464, 2019

Efficacy and safety of propranolol in the treatment of parotid hemangioma. Cutaneous and Ocular Toxicology 30(3): 245-248, 2011

Safety of Oral Propranolol for Infantile Hemangioma. Pediatrics 141(6):, 2018

Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. European Journal of Pediatrics 170(4): 493-501, 2011

Safety of Propranolol Therapy for Severe Infantile Hemangioma. JAMA 315(4): 413-415, 2016

Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and Reconstructive Surgery 128(3): 743-752, 2011

Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and Reconstructive Surgery 129(5): 840e, 2012

Discussion: Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Plastic and Reconstructive Surgery 128(3): 753-754, 2011